Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/25922
Title: Choosing Wisely in radiation therapy for breast cancer: Time lag in adoption of hypofractionated radiation therapy in Victoria.
Austin Authors: Ong, Wee Loon ;Khor, Richard ;Chao, Michael ;Milne, Roger L;Millar, Jeremy;Foroudi, Farshad 
Affiliation: Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Victoria, Australia
Precision Medicine, School of Clinical Science, Monash Health, Melbourne, Victoria, Australia
Genesis Cancer Care, Ringwood, Victoria, Australia
School of Clinical Medicine, University of Cambridge, Cambridge, UK
Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
Radiation Oncology
Olivia Newton-John Cancer Wellness and Research Centre
Alfred Health Radiation Oncology Services, Prahran, Victoria, Australia
Central Clinical School, Monash University, Melbourne, Victoria, Australia
Cancer Epidemiology Division, Cancer Council Victoria, Melbourne, Victoria, Australia
Centre for Epidemiology and Biostatistics, School of Population and Global Health, University of Melbourne, Melbourne, Victoria, Australia
Issue Date: 16-Feb-2021
metadata.dc.date: 2021-02-16
Publication information: Journal of Medical Imaging and Radiation Oncology 2021; online first: 16 February
Abstract: To evaluate the adoption of hypofractionated radiotherapy (HFRT) for breast cancer (BC) in Victoria, Australia. This is a population-based cohort of women with BC who had breast RT as captured in the Victorian Radiotherapy Minimum Data Set between 2012 and 2017. We defined HFRT as < 25 fractions of RT. The pattern of HFRT use over time was evaluated with the Cochrane-Armitage test for trend. Factors associated with HFRT were identified using multivariable logistic regression. 12,717 women were included in the study. Overall, 6,653 (52%) patients had HFRT. HFRT use increased from 35% in 2012 to 66% in 2017 (P-trend < 0.001). Older women were more likely to have HFRT (74% for women aged ≥ 70 years vs. 27% for women aged < 50 years; P < 0.001). Women who had nodal irradiation were less likely to have HFRT compared with those who did not (13% vs. 57%; P < 0.001). HFRT use was more common in public than private institutions (57% vs. 46%, P < 0.001), and in metropolitan than regional centres (54% vs. 46%, P < 0.001). In multivariable analyses, the progressive increase in HFRT use over time was independent of other covariates - women treated in 2017 were 7.3 times (95% CI = 6.3-8.6, P < 0.001) more likely to be treated with HFRT than in 2012. Age at RT, nodal irradiation, area of residence and institutional type and locations were all independently associated with HFRT use. This large Australian contemporary population-based study demonstrates increasing use of HFRT for BC. However, large sociodemographic and institutional provider-related variations in practice still exist.
URI: https://ahro.austin.org.au/austinjspui/handle/1/25922
DOI: 10.1111/1754-9485.13155
ORCID: 0000-0001-6657-7193
0000-0001-8387-0965
PubMed URL: 33591610
Type: Journal Article
Appears in Collections:Journal articles

Show full item record

Page view(s)

14
checked on Jun 19, 2021

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.